This CME Activity has expired and is no longer available for credit.
High-Risk ACS: Overcoming the Limitations of Current Anticoagulant Therapy - Dialogue with the Experts A Learner Interactive Case-Based CME Activity
Time to Complete
December 20, 2012
December 20, 2013
1.50 / AMA PRA Category 1 Credit(s)TM
This activity is jointly sponsored by Beth Israel Medical Center & St. Luke’s and Roosevelt Hospitals, and Health Education Alliance, Inc.
This activity is supported by an educational grant from sanofi-aventis U.S. Inc., a SANOFI COMPANY.
In acute coronary syndrome (ACS) patients, including those at high risk, antithrombotic therapy is key in the prevention of primary and recurrent atherothrombotic events, and also in the prevention of ischemic complications. In fact, the development of antiplatelet and antithrombotic medications and invasive vascular procedures have decreased the rates of mortality and subsequent cardiac events in ACS patients; yet patients experience recurrent clinical thrombotic events at a rate approaching 10% in the following year.
Utilizing an audience interactive format, this case-based activity will provide an opportunity for expert faculty dialogue/commentary, and will address the clinical implications of current guidelines for use of anticoagulant therapy in ACS patients, the role of thrombin in normal hemostasis and pathologic thrombosis, the relationship between bleeding and outcomes in ACS, and efficacy and safety data from recent and ongoing trials of novel anticoagulant therapies being studied in ACS patients.
Interventional cardiologists and other interested clinicians involved in the care and management of patients with ACS.
At the end of this online enduring material, participants should be able to:
Demonstrate an awareness of the most recent guideline recommendations for the use of anticoagulant therapy in ACS patients
Describe the role of thrombin in normal hemostasis and pathologic thrombosis and recognize how its inhibition can be achieved either directly or through inhibition of factor Xa
Recognize the differences in bleeding definitions used in research trials of anticoagulants and the relationship between bleeding and outcomes in ACS so that bleeding-risk assessment can be incorporated into the therapeutic decision-making process for every patient
Compare the efficacy and safety data from recent and ongoing trials of novel anticoagulant therapies being studied in ACS patients and recognize how they may overcome some of the limitations of the current standard of care
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Professor of Medicine, Harvard Medical School Chief of Cardiology, VA Boston Healthcare System Director, Integrated Interventional Cardiovascular Program, Brigham and Women's Hospital & VA Boston Healthcare System Senior Investigator, TIMI Study Group Boston, MA
Roxana Mehran, MD, FACC, FACP, FCCP, FESC, FAHA, FSCAI Professor of Medicine and Health Policy Director of Interventional Cardiovascular Research and Clinical Trials Zena and Michael A. Weiner Cardiovascular Institute Mount Sinai School of Medicine New York, NY
Professor Philippe Gabriel Steg Hôpital Bichat, Assistance Publique - Hôpitaux de Paris INSERM U-698 Université Paris-Diderot Paris, France
CME Reviewer John T. Fox, MD, FACC, FSCAI Director, Cardiac Catheterization Lab and Interventional Cardiology Beth Israel Medical Center Assistant Professor of Medicine Albert Einstein College of Medicine New York, NY
AMA PRA Category 1 Credit(s)TM
For full program information, please click on “START ACTIVITY” button and follow the next click-through to reach this program site. Once you get to the “CME Access” site description page, you will review program information, program content, take the test and receive credit.
If you have any questions relating to the accreditation or your certificate for this activity, please contact the program sponsors.